BioStem Technologies, Inc., a leading MedTech (medical technology) company specializing in placental-derived biologics for advanced wound care, unveiled its new product line, American Amnion, at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference in Phoenix, Arizona, from December 10-13, 2025.
American Amnion AC is an allograft made from human connective tissue, specifically a dehydrated layer of human amnion and chorion membrane (DHACM), including the intermediate layer. The standard American Amnion is made from only the amnion membrane (DHAM), also with the intermediate layer. Both are designed to be used as protective coverings for acute or chronic wounds. These products are made using BioStem’s unique BioRetain® technology, which preserves the natural structure and molecular makeup of the tissue.
Studies have shown that allografts made with BioRetain® technology provide superior clinical results. A recent study published in the International Journal of Tissue Repair (2025) found that patients treated with BioRetain-preserved amniochorion had nearly double the wound closure rate compared to those treated with standard care. Another study in Health Science Reports (2024) showed that BioRetain-preserved products were more effective and cost-efficient than leading competitors, closing wounds faster and requiring fewer treatments.
In addition to its clinical work, BioStem is also supporting veterans. The company is the exclusive sponsor of the Florida Panthers’ Heroes Among Us program, which honors U.S. military veterans at each home game at the Panthers’ Amerant Bank Arena in Sunrise, FL, near BioStem’s global headquarters in Pompano Beach.
Executive Statement
According to Jason Matuszewski, CEO and Chairman of BioStem Technologies, Veterans represent a significantly underserved population with a disproportionately high risk of chronic, non-healing wounds. The introduction of American Amnion is a meaningful step forward in advancing the standard of care for these patients. The use of placental-based products has increased by 50% over the last five years in the VA system. By bringing innovative, evidence-driven solutions to market, they are not only improving outcomes and quality of life for our veterans, but also helping our clinician partners deliver more efficient, cost-effective care.
